Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

0.71USD
17 May 2019
Change (% chg)

$-0.04 (-5.33%)
Prev Close
$0.75
Open
$0.74
Day's High
$0.75
Day's Low
$0.70
Volume
366,799
Avg. Vol
1,079,766
52-wk High
$3.58
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Aveo Pharmaceuticals Posts Q1 Revenue $1.6 Million Versus $1 Million
Thursday, 9 May 2019 

May 9 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 REVENUE $1.6 MILLION VERSUS $1.0 MILLION.Q1 LOSS PER SHARE $0.06.Q1 REVENUE ESTIMATE $2.2 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA.  Full Article

Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM.AVEO PHARMACEUTICALS INC - ENTERED AV380 AGREEMENT WITH NOVARTIS TO ESTABLISH, CLARIFY TERMS ON WHICH AV380 PROGRAM WILL BE RETURNED TO CO.AVEO PHARMACEUTICALS INC - NOVARTIS WILL MAKE A ONE-TIME PAYMENT TO AVEO OF $2.3 MILLION ON OR BEFORE JANUARY 2, 2019.AVEO PHARMACEUTICALS INC - NOVARTIS WILL PROVIDE THE AV380 DRUG SUPPLY, VALUED AT APPROXIMATELY $4.0 MILLION, TO AVEO AT NO CHARGE.AVEO PHARMACEUTICALS - INTENDS TO USE $2.3 MILLION PAYMENT TO COVER MILESTONE OBLIGATION DUE IN JAN 2019 TO ST. VINCENT’S HOSPITAL SYDNEY - SEC FILING.AVEO PHARMACEUTICALS - NOVARTIS WILL NOT DEVELOP, MANUFACTURE/COMMERCIALIZE ANY ANTI-GDF15 ANTAGONIST ANTIBODY FOR 3 YRS AFTER DATE OF AV380 AGREEMENT.AVEO - DEAL PROVIDES FOR CONTINUED TRANSFER TO CO OF PRECLINICAL, TECHNICAL, MANUFACTURING, OTHER DATA, MATERIALS DEVELOPED BY NOVARTIS.  Full Article

Aveo Q3 Loss Per Share $0.18
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.18.Q3 REVENUE $2.5 MILLION VERSUS $4.6 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S.$20.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AT END OF Q3 2018.BELIEVES CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WOULD ALLOW TO FUND PLANNED OPERATIONS INTO Q2 OF 2019.  Full Article

Aveo Prices Public Offering Of 2.5 Mln Common Shares At $2.26 Per Share
Friday, 17 Aug 2018 

Aug 17 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ANNOUNCES PRICING OF $5.7 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.50 MILLION COMMON SHARES PRICED AT $2.26PER SHARE.  Full Article

Aveo Quarterly Loss Per Share $0.08
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AVEO PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.08.AVEO PHARMACEUTICALS INC QUARTERLY COLLABORATION AND LICENSING REVENUE$82,000 VERSUS $127,000.  Full Article

AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA.AVEO PHARMACEUTICALS INC - ‍RECOMMENDATION TRIGGERS $2MLN MILESTONE PAYMENT FROM EUSA TO AVEO​.  Full Article

Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT.AVEO- UNDER MOU, AGREED FOR PLAINTIFFS TO CAUSE SOME OF CO'S, INDIVIDUAL DEFENDENTS' INSURANCE CARRIERS TO PROVIDE THE CLASS WITH $15 MILLION CASH PAYMENT.AVEO PHARMACEUTICALS SAYS ADDITIONALLY, CO AGREED TO ISSUE TO THE CLASS WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF AVEO COMMON STOCK - SEC FILING.AVEO PHARMACEUTICALS - IN CONSIDERATION OF SETTLEMENT PAYMENT, PLAINTIFFS AGREED THAT SETTLEMENT WILL INCLUDE DISMISSAL OF CLASS ACTION WITH PREJUDICE.AVEO PHARMA - CONSIDERING SETTLEMENT PAYMENT, PLAINTIFFS AGREED SETTLEMENT WILL INCLUDE RELEASE OF ALL CLAIMS AGAINST CO, INDIVIDUAL DEFENDANTS BY THE CLASS.  Full Article

Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aveo Pharmaceuticals Inc :AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.22.‍BELIEVE THAT OUR $37.4 MILLION IN CASH RESOURCES WOULD ALLOW US TO FUND OUR PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in
Wednesday, 20 Sep 2017 

Sept 20 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​.Aveo - ‍under terms of agreement, EUSA may utilize data from study for regulatory/commercial purposes in exchange for research and development funding payment of $2.0 million​.Aveo Pharmaceuticals Inc - ‍EUSA Pharma agreed to pay co milestone payments under terms of agreement from Dec 2015 ​.  Full Article

BRIEF-Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program

* AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM